February 24, 2024

Medical Trend

Medical News and Medical Resources

Newly isolated antibodies: Repeated booster vaccines may not be required in the future

Newly isolated antibodies: Repeated booster vaccines may not be required in the future


Newly isolated antibodies can neutralize known COVID-19 strains and repeated booster vaccines may not be required in the future.

Israeli scientists have made breakthroughs in COVID-19 antibody research.

New research has demonstrated that two antibodies isolated from the immune systems of recovered COVID-19 patients can effectively neutralize all known COVID-19 strains, including Delta and Omicron variants, with a maximum neutralization efficacy of 97%.

The finding may eliminate the need for repeated booster vaccinations and boost immunity in high-risk groups.

The research was published in a recent issue of the journal Nature Communications Biology.



Newly isolated antibodies: Repeated booster vaccines may not be required in the future



This study is a continuation of an initial study conducted in October 2020 at the height of the COVID-19 pandemic.

The team of Dr. Natalia Freund of Tel Aviv University sequenced all B immune system cells in the blood of Israeli patients recovered from the original COVID-19 strain and isolated nine antibodies produced by the patients.

The researchers found that some of these antibodies were very effective at neutralizing the COVID-19 variants (Delta and Omicron).


The new study demonstrates that two of the antibodies, TAU-1109 and TAU-2310, which bind to a region of the viral spike protein that is different from the region where most antibodies have concentrated to date, are highly effective at neutralizing the delta and omicron variants.

According to the results of the study, the first antibody, TAU-1109, was 92% effective in neutralizing the Omicron variant and 90% effective in neutralizing the delta variant; the second antibody, TAU-2310, neutralized the Omicron variant.

The variant was 84% ​​effective and the neutralized delta variant was 97% effective.


The researchers explain that the surprising efficacy of these antibodies may have something to do with the evolution of the virus: The virus’s infectivity increases with each variant, because each time, it changes the amino acid sequence of the part of the spike protein that interacts with the ACE2 receptor. combined, thereby increasing its infectivity, while avoiding the natural antibodies produced after vaccination.

In contrast, the antibodies TAU-1109 and TAU-2310 do not bind to the ACE2 receptor binding site, but to another region of the spike protein, a viral spike that for some reason does not mutate a lot. protruding regions, so they can effectively neutralize more virus variants.

These are what researchers found after testing all known strains of the COVID-19 so far.


Dr. Freund believes that antibodies could bring a real revolution in the fight against COVID-19: Targeted therapy with antibodies and delivering them in high concentrations into the body could be an effective alternative to repeated booster immunizations, especially for High-risk groups and those with weakened immune systems.

SARS-CoV-2 infection can cause severe illness, and providing antibodies in the first few days of infection can stop the spread of the virus.

Therefore, with effective antibody therapy, it may not be necessary to give the entire population a booster vaccine each time a new variant emerges.





Newly isolated antibodies: Repeated booster vaccines may not be required in the future

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.